Product Information
INCRUSE ELLIPTA 62.5 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $10.2771 per EA under NDC 00173087306. Its NADAC has been published 429 times since Apr 20, 2016.
FDA first approved this application on Apr 30, 2014.
Strength
62.5 ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173087306
Classification
Brand
Dosage Form
AEROSOL, POWDER
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
UMECLIDINIUM BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA205382FDA Approved
4/30/2014
On Market Since
4/30/2014
Pharmacological Classes
Price Statistics
The NADAC for INCRUSE ELLIPTA 62.5 MCG INH has been published 429 times since Apr 20, 2016, and over the history we have for it it has risen 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.2771 per EA |
|---|---|
| All-time high | $10.2948 (Jun 11, 2025) |
| All-time low | $8.7322 (Apr 20, 2016) |
| 52-week high | $10.2866 |
| 52-week low | $10.2428 |
| Median price | $9.9663 |
| Average price | $9.8487 |
| Largest weekly change | +9.0% (Oct 12, 2016) |
| Weeks tracked | 429 |
| Tracking since | Apr 20, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
umeclidinium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INCRUSE ELLIPTA 62.5 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for INCRUSE ELLIPTA 62.5 MCG INH, manufactured by GlaxoSmithKline LLC, is $10.2771 per EA (NDC 00173087306), effective Sep 30, 2026.
How has the price of INCRUSE ELLIPTA 62.5 MCG INH changed over time?
Over the history we have for it, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has risen 17.7%. It has been tracked across 429 weekly CMS publications since Apr 20, 2016.
What are the highest and lowest recorded NADAC prices for INCRUSE ELLIPTA 62.5 MCG INH?
Since Apr 20, 2016, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has ranged from a low of $8.7322 (Apr 20, 2016) to a high of $10.2948 (Jun 11, 2025), with a median of $9.9663 per EA.
Are there cheaper alternatives to INCRUSE ELLIPTA 62.5 MCG INH?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as INCRUSE ELLIPTA 62.5 MCG INH in a comparable dosage form, but none are currently priced below it.
Who manufactures INCRUSE ELLIPTA 62.5 MCG INH?
INCRUSE ELLIPTA 62.5 MCG INH (NDC 00173087306) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.